Recent advancements in immune checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) and anti-programmed cell death-(ligand)1 (anti-PD-(L)1), have become the standard treatment, improving outcomes for various cancers, including HCC. Here, CTLA4 is linked to hepatocellular carcinoma.